Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study for Tysabri Participant Preference
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 318
- Registration Number
- NCT05304520
- Locations
- 🇩🇪
Katholisches Klinikum Bochum gGmbH, Bochum, Germany
🇩🇪Neurologie am Mexikoplatz, Berlin, Germany
🇩🇪Neurologie Neu-Ulm, Neu-Ulm, Germany
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 21
- Registration Number
- NCT05265728
- Locations
- 🇯🇵
National Center of Neurology and Psychiatry, Kodaira-shi, Japan
🇯🇵St.Marianna University Hospital, Kawasaki-shi, Japan
🇯🇵Chiba University Hospital, Chiba-shi, Japan
TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 675
- Registration Number
- NCT05236777
- Locations
- 🇨🇿
Fakultní nemocnice v Plzni, Pilsen, Czechia
🇨🇿Fakultní nemocnice Olomouc, Olomouc, Czechia
🇨🇿Fakultní nemocnice v Ostravě, Ostrava, Czechia
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 84
- Registration Number
- NCT05229562
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- Biological: Aducanumab
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 123
- Registration Number
- NCT05216887
- Locations
- 🇺🇸
QPS Missouri, Springfield, Missouri, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸QPS-MRA, Miami, Florida, United States
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
- Conditions
- Multiple Sclerosis (MS)
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 160
- Registration Number
- NCT05197699
- Locations
- 🇩🇪
Multiple Sklerose Zentrum, Bamberg, Germany
🇩🇪Universitätsklinikum Tübingen, Neurologie, Tübingen, Germany
🇩🇪St. Josef Hospital, Klinikum der Ruhr-Universität Bochum, Bochum, Germany
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 72
- Registration Number
- NCT05195008
- Locations
- 🇬🇧
Medicines Evaluation Unit, Wythenshawe, Manchester, United Kingdom
🇸🇪Karolinska Comprehensive Cancer Center - Studieenheten, Flemingsberg, Stockholm, Sweden
🇬🇧Hammersmith Medicine Research, London, Brent, United Kingdom
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
- Conditions
- Spinocerebellar Ataxia Type 3
- Interventions
- Drug: BIIB132-Matching Placebo
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 8
- Registration Number
- NCT05160558
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸University of Florida, Center for Movement Disorders, Gainesville, Florida, United States
🇵🇹Centro Hospitalar do Porto, Porto, Portugal
A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BIIB104 Test FormulationDrug: BIIB104 Reference Formulation
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT05152485
- Locations
- 🇺🇸
QPS MRA, Miami, Florida, United States
A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 31
- Registration Number
- NCT05148481
- Locations
- 🇺🇸
Research Site, Anaheim, California, United States